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OBJECTIVES We performed positron emission tomography (PET) to evaluate myocardial ischemia in
patients with idiopathic dilated cardiomyopathy (IDC).
BACKGROUND Patients with IDC have anatomically normal coronary arteries, and it has been assumed that
myocardial ischemia does not occur.
METHODS We studied 22 patients with IDC and 22 control subjects using PET with nitrogen-13
ammonia to measure myocardial blood flow (MBF) at rest and during dipyridamole-induced
hyperemia. To investigate glucose metabolism, fluorine-18 deoxyglucose (18FDG) was used.
For imaging of oxygen consumption, carbon-11 acetate clearance rate constants (kmono) were
assessed at rest and during submaximal dobutamine infusion (20 mg/kg body weight per min).
RESULTS Global MBF reserve (dipyridamole-induced) was impaired in patients with IDC versus
control subjects (1.7 6 0.21 vs. 2.7 6 0.10, p , 0.05). In patients with IDC, MBF reserve
correlated with left ventricular (LV) systolic wall stress (r 5 20.61, p 5 0.01). Furthermore,
in 16 of 22 patients with IDC (derived by dipyridamole perfusion) mismatch (decreased
flow/increased 18FDG uptake) was observed in 17 6 8% of the myocardium. The extent of
mismatch correlated with LV systolic wall stress (r 5 0.64, p 5 0.02). The MBF reserve was
lower in the mismatch regions than in the normal regions (1.58 6 0.13 vs. 1.90 6 0.18, p ,
0.05). During dobutamine infusion kmono was higher in the mismatch regions than in the
normal regions (0.104 6 0.017 vs. 0.087 6 0.016 min21, p , 0.05). In the mismatch regions
18FDG uptake correlated negatively with rest kmono (r 5 20.65, p , 0.05), suggesting a
switch from aerobic to anaerobic metabolism.
CONCLUSIONS Patients with IDC have a decreased MBF reserve. In addition, low MBF reserve was
paralleled by high LV systolic wall stress. These global observations were associated with
substantial myocardial mismatch areas showing the lowest MBF reserves. In geographically
identical regions an abnormal oxygen consumption pattern was seen together with a switch
from aerobic to anaerobic metabolism. These data support the notion that regional
myocardial ischemia plays a role in IDC. (J Am Coll Cardiol 2000;35:19–28) © 1999 by the
American College of Cardiology
Idiopathic dilated cardiomyopathy (IDC) is a primary
myocardial disease of unknown origin, characterized by a
poorly contracting and dilated left or right ventricle (1).
Idiopathic dilated cardiomyopathy leads to symptomatic
congestive heart failure (CHF) in the majority of patients
and carries a high morbidity and mortality rate (2). It has
generally been assumed that in patients with IDC, myocar-
dial ischemia does not play a role, because they have, by
definition, anatomically normal epicardial coronary arteries.
However, recent studies have shown that endothelial func-
tion is impaired in patients with IDC (3) and that myocar-
dial perfusion abnormalities occur (4). It is unknown
whether this leads to abnormal metabolism compatible with
myocardial ischemia.
Dynamic positron emission tomographic (PET) imaging
permits noninvasive quantitation of myocardial blood flow
(MBF) and metabolism by using positron-emitting imaging
tracers taken up by the myocardium (5). Myocardial blood
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flow is estimated using nitrogen-13 (13N)-ammonia as a
perfusion tracer (6,7), both at rest and after application of
vasodilating agents such as dipyridamole to assess MBF
reserve. Fluorine-18 deoxyglucose (18FDG) is a positron-
emitting metabolic imaging tracer with higher uptake by the
myocardium in the presence of chronic ischemia and low
uptake in infarct-related regions. Simultaneous imaging
with 13N-ammonia and 18FDG can demonstrate regions of
mismatch, where reduced uptake of 13N-ammonia but
retained uptake of 18FDG is indicative of viable myocar-
dium (8). These mismatch patterns have been shown to be
a good marker for identifying myocardial viability in pa-
tients with coronary artery disease (9). In addition to these
tracers, carbon-11 (11C)-acetate is used to quantitate myo-
cardial oxidative metabolism. This tracer enters the mito-
chondria and participates as 11C-acetyl-coenzyme A in the
tricarboxylic acid cycle. The 11C activity is released from the
myocardium as [11C]CO2. Both monoexponential and
biexponential clearance of 11C activity from the myocar-
dium after intravenous injection of 11C-acetate (10,11) is
used to estimate oxygen consumption. Quantification of the
clearance kinetics of this tracer from the myocardium allows
estimation of myocardial oxygen consumption. Increased
cardiac work load is associated with an increase in the
11C-acetate clearance rate constant (kmono) (11). These
characteristics make 11C-acetate a useful tracer for clinical
research to determine myocardial oxygen consumption.
The present study investigated whether MBF reserve im-
pairment in patients with IDC is related to ischemic changes,
thereby playing a potential role in the development or progres-
sion of the disease. We examined MBF and MBF reserve,
myocardial glucose metabolism and oxygen consumption in
patients with IDC using PET, and we compared these data
with those of a group of age- and gender-matched normal
volunteers (control subjects). Further, we investigated echocar-
diographic left ventricular (LV) wall stress, which is a well-
known factor determining MBF.
METHODS
Study group. Patients with IDC and mild to moderate
CHF were eligible for the study and were compared with a
group of age- and gender-matched healthy volunteers (con-
trol subjects). All patients underwent coronary angiography,
which showed normal epicardial coronary arteries. The
diagnosis of IDC, on the basis of a combination of clinical
variables (LV dilation, global decreased contraction pat-
terns), was supported by endomyocardial biopsy. In all 22
patients, microscopic features included hypertrophy as well
as degeneration of myocytes and varying degrees of inter-
stitial fibrosis. At baseline, within seven days of PET, the
severity of CHF was assessed by scoring functional class
according to the New York Heart Association (NYHA), by
measuring LV ejection fraction (LVEF) using equilibrium
radionuclide ventriculography and by determining peak
oxygen consumption (V˙O2max) on a treadmill with respira-
tory gas exchange measurements as previously described
(12). All patients had to be clinically stable on angiotensin-
converting enzyme (ACE) inhibitors, diuretics and digoxin.
Other vasoactive medications, including beta-blockers, were
not allowed. Patients with systemic hypertension (systolic
blood pressure .150 mm Hg, diastolic blood pressure
.95 mm Hg), diabetes mellitus, hypercholesterolemia
(.6 mmol/liter) or any other systemic illness were excluded.
Healthy control subjects were selected from our data base
and matched for age and gender. All participants underwent
a physical examination, electrocardiogram and laboratory
analysis (total cholesterol, renal function, electrolytes, he-
moglobin). All patients gave written, informed consent, and
the protocol was approved by the Institutional Review
Board.
Protocol for PET imaging. The PET studies were per-
formed after patients (and control subjects) had refrained
from medical therapy for five plasma half-lives and caffein-
ated beverages for 24 h before the studies. Patients were
positioned in a 951 Siemens (ECAT) positron camera
(Siemens AG, Knoxville, Tennessee), which images 31
planes simultaneously over 10.8 cm (axial field of view).
Data were automatically corrected for accidental coinci-
dence and dead time. Subjects were positioned with the help
of a rectilinear scan. Photon attenuation was measured using
a rectilinear external ring source filled with 68Ge/68Ga.
Patients were constantly monitored with 12-lead electrocar-
diography, and blood pressure was measured automatically
every 10 min and every minute during dipyridamole and
dobutamine infusion. Myocardial blood flow was studied
according to the methods of Schelbert et al. (6) and Bellina
et al. (7), as previously described (13), using 13N-ammonia
as the tracer. Dynamic rest imaging was started at the time
of 13N-ammonia injection (370 MBq) and continued
for 15 min (frames 12 3 10 s, 1 3 2 min, 1 3 4 min,
1 3 7 min). Dipyridamole stress imaging was performed by
infusing dipyridamole (0.56 mg/kg body weight in 4 min).
Imaging was done by injecting 370 MBq of 13N-ammonia
6 min after the start of dipyridamole infusion and continued
for 15 min (frames 12 3 10 s, 1 3 2 min, 1 3 4 min,
1 3 7 min). After this, myocardial glucose uptake was
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studied with 18FDG, using the methods of Choi et al. (14).
To stimulate myocardial glucose uptake, patients were given
75 g of glucose orally before the scanning procedure. The
FDG imaging was done 5 min after injecting 185 MBq
of 18FDG and continued for 35 min (frames 8 3 15 s,
4 3 30 s, 1 3 1 min, 1 3 5 min, 1 3 10 min, 1 3 15 min).
On a separate day, within 1 week of 13N-ammonia and
18FDG PET imaging, oxidative metabolism was deter-
mined by measuring the 11C-acetate clearance rate con-
stants (kmono) (10). Data correction, positioning and photon
attenuation were done as described earlier. Carbon-11–
acetate rest imaging was performed by injecting 370 MBq
of 11C-acetate, and imaging was done for 35 min (frames
12 3 10 s, 8 3 1 min, 5 3 2 min, 5 3 3 min). Then
dobutamine infusion was started at 5 mg/kg per min. The
dose was increased with 5 mg/kg per min every 2 min until
20 mg/kg per min maximum was achieved. Infusion was
continued at 20 mg/kg per min for the rest of the study
to maintain a constant rate–pressure product, and 11 min
after the start of dobutamine infusion 370 MBq of 11C-
acetate was injected. Imaging continued for 20 min (frames
12 3 10 s, 8 3 1 min, 5 3 2 min).
Analysis of PET data. The data from the dipyridamole
13N-ammonia and 18FDG and the dobutamine 11C-acetate
studies were corrected for remaining activity by subtracting
the last frame of the preceding study (13). After this
subtraction procedure, data for each study were reoriented
to 10 short-axis images using a manually drawn long axis in
the left ventricle. The myocardium in the 10 slices was
divided into 48 segments (7.5° each). Using the maximal
activity, time-activity curves were established in all segments
of all slices (15). The blood pool was defined in three slices
near the base, the average of which was used to calculate a
single blood-pool time-activity curve. For each of the 480
segments MBF was calculated using a curve fit over 120 s.
As this apparent flow-time curve is noisy, an exponential fit
of the total data set was calculated, and the flow was
measured at 90 s. To compensate for flow-mediated extrac-
tion, a correction was applied as given by Shah et al. (16):
E 5 E0 z (1 2 0.607 z e
21.25/flow). For calculation of glucose
consumption, myocardial and blood-pool time-activity
curves were used to perform Patlak analysis (17). This
technique is used in general models in which the tracer is
irreversibly trapped in a system. It was proposed and
described by Patlak and Blasberg (17). Data obtained from
5-min postinjection were used to calculate the slope of the
Patlak curve. This graphic approach permits the calculation
of regional 18FDG uptake by giving a direct estimate of the
slope of the linear relationship on the plot. To assess
oxidative metabolism, 11C-acetate clearance rate constants
(Kmono) were obtained from the decay-corrected
11C-
acetate time-activity curves by least-square monoexponen-
tial curve fitting, as previously described (10). For each
individual segment myocardial perfusion, glucose metabo-
lism and oxidative metabolism were calculated. From these
data a parametric polar map for each modality was con-
structed—for the 13N-ammonia perfusion studies using the
aforementioned perfusion model (15), for the 18FDG stud-
ies using Patlak analysis (17) and for 11C-acetate using the
clearance rate constants (kmono) (10). From the polar maps
of the control case and after provocation with dipyridamole
and dobutamine, ratio polar maps were constructed for
MBF and oxidative metabolism, respectively. From the
normal volunteers’ data, we defined 95% confidence inter-
vals (CIs) of the normal values for each imaging modality
for each of the 480 segments (from mean 22 3 SD to mean
12 3 SD) (13,17). Patient data were then compared with
these intervals in each imaging modality, resulting in a 95%
confidence map for each imaging modality. This compari-
son shows which myocardial segment is within, above or
below the corresponding 95% CI. In this way the percent
myocardium above and below the 95% CI could be calcu-
lated. Global measurements are presented as the mean of
the 480 segments. The parametric polar map, displaying
480 segments (13), obviates tedious selection of regions of
interest. This enables selection of the three different kinds of
regions (normal, match and mismatch) and to calculate flow
reserve (13N-ammonia), glucose metabolism (18FDG up-
take) and oxygen consumption (11C-acetate clearance rates)
in these three separate regions of interest.
Definition of blood flow (13N-ammonia) vs. 18FDG
(mismatch and match). Vanoverschelde et al. (18) showed
that dipyridamole-derived myocardial perfusion correlates
better with the extent of wall motion abnormalities in
hibernating myocardium, as compared with rest perfusion.
Therefore, to calculate mismatch (and match) we used the
dipyridamole-derived blood flow. To quantify mismatch,
the parametric 18FDG uptake polar map and hyperemic
blood flow polar map were normalized to their mean values.
A difference polar map was constructed by subtracting the
normalized hyperemic MBF polar map from the normalized
18FDG polar map. The percent myocardium above the 95%
CI of a normal data base was calculated (Fig. 1). The results
are expressed as percent total myocardium. Similarly, quan-
titation of match areas was determined from a product polar
map by multiplying the normalized 18FDG and the nor-
malized dipyridamole-induced perfusion and by calculating
the percent myocardium below the 95% CI.
Measurement of LV wall stress. Left ventricular wall
stress was measured using echocardiography (19). In short,
echocardiograms were recorded by a single operator, using a
2.5-MHz probe (Sonotron/Vingmed sound, Zoetermeer,
The Netherlands); noninvasive blood pressure was mea-
sured simultaneously by the cuff manometer. Left ventric-
ular internal diameter and wall thickness were obtained
from M-mode tracings in the plane of the mitral valve
during two-dimensional echocardiography. Left ventricular
systolic wall stress was determined by the equation: s 5
(0.334 P [LVID])/(PWT [1 1 PWT/LVID]), where P is
the mean of duplicate cuff arterial systolic pressure; LVID is
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the LV systolic (smallest) internal diameter; and PWT is
the systolic posterior wall thickness at the time of the
smallest LVID. Data were analyzed as the mean of three to
five cardiac cycles. For LV end-diastolic wall stress, P was
the LV end-diastolic pressure obtained during angiography,
which was performed within one day from the echocardio-
gram and 13N-ammonia PET imaging, without changes in
medication during the period between the three investiga-
tions; LVID was the LV diastolic (largest) internal diame-
ter; and PWT was the diastolic posterior wall thickness at
the time of the largest LVID. Normal systolic wall stress in
our echocardiography laboratory is 106 6 11 3 103 dynes/
cm2; normal diastolic wall stress is 7.3 6 3 3 103 dynes/
cm2.
Statistical analysis. Global data are presented as the mean
of 480 segments of the polar map. Data of three regions are
presented, which are the mean of the regions with a normal,
mismatch or match pattern. Values are given as the mean
value 6 SD. Group differences of perfusion dynamics were
obtained using a Wilcoxon two-sample test on the deltas
from baseline and during dipyridamole and dobutamine.
The data of the three different regions (normal, mismatch
and match) were compared by two-way analysis of variance
with a Bonferroni correction. The Spearman rank-order
correlation coefficient was used to investigate the associa-
tions between study variables. Differences with a p value
,0.05 were considered statistically significant. Statistical
analysis was performed using SAS statistical software, ver-
sion 6.08. Myocardial blood flow was given in milliliters per
minute/100 g, and glucose utilization in micromoles per
minute/100 g. A flow-metabolism (13NH3/18FDG) mis-
match pattern was represented as percent total myocardium.
Oxidative metabolism (11C-acetate clearance) was given as
the rate constant (kmono) per minute.
Figure 1. Example of PET polar maps. In healthy volunteers (three polar maps at right) MBF reserve (top polar map; 280% 5 ratio 2.8)
and 18FDG uptake (middle polar map; 51 mmol/min per 100 g) are more or less homogeneously distributed throughout the left ventricle.
The PET polar maps in a patient with IDC (three polar maps at left) show confluent regions with mismatch (bottom polar map) (i.e.,
impaired flow reserve [top polar map; mean 210% 5 ratio 2.1]) paralleled by increased 18FDG uptake (mean 60 mmol/min per 100 g).
Flow reserve units are percent hyperemic blood flow related to rest blood flow. Mismatch units are presented as standard deviations of a
normal data base. A 5 anterior; L 5 lateral; I 5 inferior; S 5 septal.
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RESULTS
Twenty-two patients with IDC and mild to moderate CHF
were studied (Table 1). Total cholesterol was 5.2 6 0.4
mmol/liter and the rest plasma norepinephrine con-
centration was 617 6 20 pg/ml (normal range 100 to
500 pg/ml). The patients with IDC were compared with 22
age- and gender-matched healthy control subjects (14 men,
age 44 6 14 years, total cholesterol 5.3 6 0.30 mmol/liter).
All patients were taking an ACE inhibitor, diuretic agents
and digitalis, which were discontinued 5 plasma half-lives
before PET scanning. No patient was taking beta-blockers
or other vasoactive drugs. The PET studies for the assess-
ment of MBF, using 13N-ammonia, and assessment of
glucose utilization, using 18FDG, were available in all 22
patients with IDC and control subjects. Eight patients had
both match and mismatch, eight patients had only mis-
match and six patients had only match. Oxygen consump-
tion, as measured by 11C-acetate clearance rates, was avail-
able in 13 patients with IDC and in all healthy control
subjects. Between the two studies, patients were clinically
stable and blood pressure and heart rate (rate–pressure
product) were similar. The echocardiographic evaluation
confirmed global LV dysfunction (global hypokinesia, i.e.
impaired contraction patterns) in all patients. The LV
meridional systolic wall stress was 187 6 36 3 103 dynes/
cm2 (range 134 to 289 3 103). The LV meridional diastolic
wall stress was 33 6 18 3 103 dynes/cm2 (range 6 to 64 3
103).
Global MBF (13N-ammonia studies). At rest, global
MBF was similar between patients with IDC and healthy
control subjects (102 6 21 vs. 102 6 16 ml/min per 100 g)
(Fig. 2). In contrast, after dipyridamole infusion, global
MBF was significantly lower in patients with IDC as
compared with control subjects (166 6 36 vs. 280 6
104 ml/min per 100 g, p 5 0.03, delta between baseline and
Figure 2. Global myocardial blood flow at rest (dark hatched
bars) and after dipyridamole infusion (open bars) in patients with
CHF and IDC and in control subjects. #p , 0.05 delta flow in
healthy volunteers versus patients with IDC.

















1 45 F III 53 19.9 18 100 72
2 35 M II 23 14.2 25 110 76
3 34 M III 16 23.9 12 108 75
4 55 F II 18 27.2 8 120 50
5 27 M II 27 16.4 10 100 55
6 35 F II 53 25.9 24 110 69
7 36 F II 24 18.9 12 100 59
8 45 F III 40 22.6 30 110 61
9 54 M III 29 17.2 18 100 55
10 42 M II 29 17.2 8 100 66
11 19 M II 27 27.5 12 120 53
12 55 M III 51 23.9 32 110 54
13 40 M II 18 15.9 5 115 62
14 72 F II 21 25.3 15 100 64
15 32 M III 32 14.0 20 115 73
16 75 M II 16 20.7 20 110 58
17 71 M III 31 13.1 5 100 85
18 62 F III 15 18.9 25 105 60
19 32 M III 34 17.8 15 100 57
20 56 M III 33 33.2 20 110 66
21 50 M III 20 19.5 20 110 62
22 36 M II 23 16.1 12 110 57
mean 6 SD 46 6 15 29 6 12 20.4 6 5.2 17 6 7 107 6 7 63 6 9
F 5 female; LVEDD 5 left ventricular end-diastolic diameter; LVEDP 5 left ventricular end-diastolic pressure; LVEF 5 left ventricular ejection fraction; LVSP 5 left
ventricular systolic pressure; M 5 male; NYHA 5 New York Heart Association functional class for heart failure; V˙O2max 5 peak oxygen consumption.
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dipyridamole). Consequently, global MBF reserve was re-
duced in patients with IDC as compared with control
subjects (1.72 6 0.21 vs. 2.71 6 0.10, p 5 0.03). The
impaired MBF reserve in patients with IDC showed a
correlation with LVEF (r 5 0.4, p 5 0.02) and with
V˙O2max (r 5 0.4, p 5 0.04) (Table 2) and was significantly
lower in patients in NYHA functional class III than in those
in class II (p 5 0.004) (Fig. 3). Systolic wall stress showed
a trend toward a negative correlation with MBF at rest (r 5
20.49, p 5 0.057) and a significant correlation with MBF
during dipyridamole (r 5 20.65, p 5 0.007) (Table 2 and
Fig. 4). For diastolic wall stress there were no such (signif-
icant) correlations (Table 2).
Glucose utilization (18FDG studies). Total 18FDG uptake
in patients with IDC (50 6 20 mmol/min per 100 g) was not
different from that of healthy volunteers (60 6 18 mmol/min
per 100 g). However, when uptake of 18FDG was related to
perfusion (hyperemic 13N-ammonia studies), mismatch was
observed in 16 (76%) of the 22 patients with IDC, but in 0%
of healthy control subjects (p 5 0.003). In these 16 patients,
17.3 6 8% of the myocardium showed this mismatch pattern
(range 6% to 40%); the polar map showed clear confluent
regions with mismatch. In 14 patients, 16.4 6 9% of the
myocardium showed a match pattern (range 5% to 28%).
Further, in the patients with IDC, increased systolic wall stress
was associated with extent of mismatch (r 5 0.64, p 5 0.02)
(Table 2). For diastolic wall stress this correlation was not
significant (r 5 0.14, p 5 0.62).
Myocardial oxidative metabolism (11C-acetate studies).
Dobutamine infusion had a similar effect on the rate–
pressure product in patients with IDC and healthy volun-
teers (mean ratio 2.4 6 0.4 and 2.2 6 0.3, respectively, p 5
NS). In patients with IDC, 11C-acetate clearance (kmono) at
rest (0.057 6 0.014 min21) and after dobutamine (0.089 6
0.021 min21) was not different from that of healthy control
subjects (0.052 6 0.012 and 0.101 6 0.032 min21, respec-
tively, p 5 NS). However, the ratio of 11C-acetate clearance
(kmono dobutamine/kmono rest) in patients with IDC was
1.6 6 0.3 vs. 2.0 6 0.2 in control subjects (p 5 0.04). When
global MBF reserve was related to global kmono ratio
(increase in oxygen consumption after dobutamine) there
Figure 3. Global MBF reserve in control subjects and in patients
in New York Heart Association (NYHA) functional classes II and
III. *p , 0.05.
Figure 4. Correlation between global MBF during dipyridamole
infusion and LV systolic wall stress in patients with IDC.
Table 2. Relations Between Hemodynamic Data and PET Data







r p r p r p r p r p r p
LVEDP 0.09 0.71 20.28 0.21 0.08 0.81 20.08 0.79 20.003 0.99 0.26 0.27
LVEF 20.01 0.97 0.41 0.02 20.03 0.93 0.06 0.85 20.19 0.47 20.11 0.66
DLVWS 0.07 0.77 20.20 0.33 20.07 0.86 0.22 0.57 0.14 0.62 0.18 0.58
SLVWS 20.49 0.57 20.61 0.01 20.46 0.30 20.82 0.03 0.64 0.02 0.21 0.43
V˙O2max 20.15 0.58 0.42 0.04 20.53 0.28 20.28 0.60 0.49 0.15 20.08 0.74
*Ratio of MBF during dipyridamole and MBF at rest. †Acetate clearance rate (kmono) at rest. ‡Acetate clearance rate (kmono) during low dose (20 mg/kg per min) dobutamine
infusion.
DLVWS 5 diastolic left ventricular wall stress; LVEDP 5 left ventricular end-diastolic pressure (during left angiography); LVEF 5 left ventricular ejection fraction; match:
see text for definition; mismatch: see text for definition; MBF 5 myocardial blood flow; SLVWS 5 systolic left ventricular wall stress; V˙O2max 5 peak oxygen consumption
during exercise.
24 van den Heuvel et al. JACC Vol. 35, No. 1, 2000
Ischemia in IDC January 2000:19–28
was a nonsignificant relation (r 5 0.2, p 5 0.2) (Fig. 5A).
There was a significant negative relation between global
11C-acetate clearance rates and percent myocardium with
mismatch (r 5 20.52, p , 0.05) (Fig. 5B). Global systolic
wall stress correlated negatively with global kmono during
submaximal dobutamine infusion (r 5 20.82, p 5 0.025)
and positively with percent myocardium with match (r 5
0.61, p 5 0.02).
Regional measurements. Table 3 shows measurements in
normal regions, mismatch regions and match regions. Rest
MBF was not different between the three regions. However,
during the dipyridamole stress test, an increase in MBF was
higher in the normal regions, leading to a higher MBF
reserve (1.90 6 0.18 in normal regions; 1.58 6 0.13 in
mismatch; 1.53 6 0.10 in match). The FDG uptake was
highest in the mismatch regions (64 6 14 mmol/min per
100 g) and lowest in the match regions (43 6 12 mmol/min
per 100 g). In normal regions, FDG uptake was 56 6 12
mmol/min per 100 g. At rest, kmono (oxygen consumption)
was not different in the three regions. During dobutamine,
the increase in oxygen consumption was significantly higher
in the mismatch regions than in the normal regions (ratio
1.73 6 0.22 vs. 1.53 6 0.22, respectively). The FDG uptake
and oxygen consumption (kmono) showed a significant neg-
ative correlation (r 5 20.65, p , 0.05) in the mismatch
regions, but not in other regions.
DISCUSSION
Main findings. The present study shows normal myocar-
dial perfusion at rest but impaired MBF reserve in patients
with IDC, thereby confirming previous findings (18). Fur-
thermore, it reveals that MBF reserve impairment was
related to severity of heart failure and to systolic LV wall
stress. In addition, in the majority of patients with IDC
(76%), mismatch (perfusion/metabolism) was observed in a
substantial part of the myocardium, and in 64% of the
patients match was observed. Furthermore, although rest
global and regional oxygen consumptions were normal, a
negative correlation between rest oxygen consumption and
extent of mismatch was found, indicating regional adaption
to lowered metabolic needs at rest. In addition, oxidative
metabolism during submaximal adrenergic drive appeared
disturbed (i.e., oxygen consumption shows a more rapid
increase in mismatch regions as compared with normal
regions). Finally, in mismatch regions 18FDG uptake
showed a negative correlation with kmono at rest, suggesting
a switch from aerobic (11C-acetate clearance rate) to anaer-
obic metabolism (glucose uptake). Furthermore, high sys-
tolic wall stress was associated with reduced oxygen con-
sumption during stress and with the extent of match and
mismatch. These findings support the notion of a mainly
stress-induced imbalance between oxygen demand (oxygen
utilization) and supply, leading to regional metabolic
changes compatible with hibernation or chronic ischemia.
Decreased global flow reserve in patients with IDC. The
regulation of MBF in patients with cardiac disease is a
complex phenomenon. It depends on coronary perfusion
pressure, lumen integrity and vasomotor control in epicar-
dial conduit vessels, function of the coronary microcircula-
tion as well as extravascular forces related to intramyocardial
pressure or wall stress (20,21). In the present study, the
impairment of global MBF reserve was related to the degree
of LV dysfunction, NYHA functional class and LV systolic
wall stress. Under physiologic conditions an increase in LV
wall stress is associated with increased MBF and higher
oxygen consumption. However, under pathophysiologic
conditions, such as LV hypertrophy and cardiomyopathy,
the reverse may occur, potentially setting the stage for
myocardial ischemia. Vatner et al. (21) demonstrated in
dogs with LV hypertrophy and LV failure that that blood
flow reserve was impaired by elevated LV systolic wall stress
(most obvious in the subendocardium), which was paralleled
by myocardial ischemia, as evidenced by decreased contrac-
tility. At a later point in time myocardial fibrosis was
observed in the subendocardium. In the present study, the
Figure 5. A, Correlation between global MBF reserve and 11C-
acetate clearance rate ratio (ratio of 11C-acetate clearance rates
during dobutamine infusion and clearance rates at rest). Note that
low dose dobutamine infusion did not exhaust the dipyridamole-
determined MBF reserve. B, Correlation between global 11C-
acetate clearance rate (kmono 5 oxygen consumption) at rest and
percent myocardium showing mismatch.
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match regions might represent such regions with myocardial
fibrosis—the clinical counterpart being myocardial fibrosis
found in endomyocardial biopsies. Intrinsic functional vas-
cular wall abnormalities (e.g., endothelial dysfunction) may
also lead to impairment of MBF reserve and ischemia in
CHF (3,22,23). In addition, it may relate to high levels of
circulating vasoconstrictor neurohormones like norepineph-
rine, angiotensin II and endothelin. In addition, long-term
elevations of these neurohormones may induce structural
vascular changes that may potentially impair endothelium-
induced vasodilation of the coronary vasculature, as ob-
served in patients with hypertension (24).
Global glucose (18FDG) and oxidative (11C-acetate)
metabolism. Global data showed match and mismatch
defects concerning FDG uptake and MBF reserve in 76% of
patients with IDC but not in normal control subjects. In
general, mismatch is considered to represent a kind of
metabolic derangement if not ischemia. Mismatch and
match appeared to be confined to confluent myocardial
regions. Global rest and stress-induced oxygen consump-
tions seem normal but their ratio was significantly lower in
patients with IDC than in control subjects. This indicates
that on a global basis the increment in oxygen consumption
during adrenergic stress is less marked. Further analysis
within the group of patients with IDC revealed that this
was not necessarily due to the reduced MBF reserve seen
in our patients with IDC. Instead, decreased adrenergic-
dependent oxygen consumption seemed to be associated
with high systolic wall stress, and, in turn, high wall stress
was paralleled by a larger amount of myocardium with
mismatch. Our interpretation of these findings is that in the
course of the disease, high wall stress may provoke ischemic
conditions by limiting peak blood flow and increasing
oxygen demand, which in turn leads to hibernation and
hence decreased oxygen consumption during stress. In this
respect, it is interesting to note the inverse association
between systolic wall stress and global MBF reserve. Con-
sidering this, provocation of ischemia by high wall stress
may appear an important supervening mechanism causing
deterioration of LV function in patients with IDC, but this
notion needs further study.
Regional measurements. In the areas with “ischemic”
metabolic changes (i.e., mismatch areas) the flow reserve is
most impaired, whereas 18FDG uptake is increased in these
regions. The rest oxygen consumption (kmono) was similar
among regions that had been shown previously and may be
ascribed to a relatively high increase in oxygen extraction in
the abnormal areas (25). However, quite unexpectedly,
dobutamine stimulation provoked a significantly higher
(rather than lower) oxygen consumption in the mismatch
regions as compared with the match and normal regions.
Dobutamine (dose of 20 mg/kg per min) did not exhaust
global flow reserve (defined as dipyridamole/rest flow),
indicating that adrenergic stimulation was submaximal. The
11C-acetate findings suggest that during submaximal adren-
ergic stimulation, oxygen consumption increases faster than
it does in normal regions, suggesting higher oxygen demand
in the mismatch regions during similar stimulation. The
regionally high oxygen consumption after submaximal ad-
renergic stimulation may be due to a relative increase in
(ischemia-induced) beta-adrenoceptor density in the mis-
match regions (26) or to an increased regional LV wall stress
(27). The latter may represent higher extravascular flow
impedance and higher oxygen demand. Our 11C-acetate
data suggest that the wall motion response to submaximal
dobutamine (20 mg/kg per min) is unaffected or even
increased in the mismatch areas, rather than decreased. This
is supported by the findings of Cohen et al. (28), who found
in patients with IDC (age 57 6 12 years, LVEF 0.27 6
0.09) that the inotropic response to 40 mg/kg per min was
unchanged or increased in 21 of 22 patients. Whether all
this leads to ischemia is questionable. However, high dose
Table 3. Positron Emission Tomographic Measurements in the Three Different Regions
Mismatch Regions Match Regions Normal Regions
Percent myocardium 17.3 6 8% 16.4 6 9%
No. of patients 16 14
Rest MBF (ml/min per 100 g) 102 6 13 100 6 10 115 6 18
Dipyridamole MBF (ml/min per 100 g) 156 6 26 146 6 23 219 6 34*
MBF reserve (ratio) 1.58 6 0.13 1.53 6 0.10 1.90 6 0.18*
18FDG uptake (mmol/min per 100 g) 64 6 14* 43 6 12* 56 6 12*
Rest kmono (min
21) 0.060 6 0.011 0.056 6 0.009 0.057 6 0.010
Dobutamine kmono (min
21) 0.104 6 0.017* 0.084 6 0.018 0.087 6 0.016
kmono ratio 1.73 6 0.22* 1.50 6 0.21 1.53 6 0.22
Correlation between MBF and kmono (rest) 0.5 (p 5 NS) 0.6 (p , 0.05) 0.9 (p , 0.05)
Correlation between 18FDG and kmono (rest) 20.65 (p , 0.05) 20.25 (p 5 NS) 20.30 (p 5 NS)
*p , 0.05 vs. other two groups. Data are presented as the mean value 6 SD.
18FDG (fluorine-18 deoxyglucose) uptake 5 glucose metabolism; kmono (
11C-acetate clearance) 5 estimate of oxygen consumption; kmono ratio 5 factor indicating an increase
of oxygen consumption during low dose (20 mg/kg per min) dobutamine infusion; correlation coefficient of MBF and kmono (rest) indicates the degree to which MBF determines
oxygen consumption (see text); the correlation of 18FDG and kmono (rest) indicates the degree to which aerobic and anaerobic metabolism are linked (see text); MBF 5 myocardial
blood flow.
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dobutamine may provoke ischemia by exhausting flow
reserve, while potentially further increasing oxygen demand.
The concept of ischemia in IDC is further supported by the
presumed switch from aerobic to anaerobic metabolism in
the mismatch areas. With this concept one must assume
that ischemia is not continuously present but develops only
during intermittent high grade adrenergic stimulation lead-
ing to repetitive stunning and hibernation (29).
Study limitations. To keep the physiologic conditions
constant, we did not use the technique of hyperinsulinemic,
euglycemic clamping. With the method we employed, the
glucose uptake was probably limited by decreased insulin
sensitivity, as is often the case in CHF (30). By using the
clamping technique, glucose uptake would probably have
been higher, and thus it is possible that we underestimated
the extent of mismatch in the present study. Noninvasive
detection and quantitation of myocardial ischemia remains
difficult (31), but both 18FDG and 11C-acetate studies using
PET provide supportive data for ischemia as a mechanism.
The combination of decreased MBF reserve and increased
18FDG uptake (i.e., “mismatch” pattern) is considered to
indicate myocardial ischemia (9). Although this notion is
usually employed in patients with coronary artery disease to
assess viability (32), it was also used in the present study of
patients with IDC. In support of the use of the mismatch
notion in patients with IDC, we want to draw attention to
the fact that mismatch was not only the consequence of
reduced flow reserve but also significantly increased 18FDG
uptake. The question remains as to what triggers the
regional mismatch (i.e., local “ischemic” changes in patients
with IDC) and why certain regions are affected and others
unaffected. Furthermore, the present data cannot define the
clinical role of local ischemia in IDC. However, it is
tempting to assume that ischemia provokes progressive
deterioration of ventricular function. How far the mismatch
areas may normalize again in terms of flow, metabolism and
oxygen consumption, or deteriorate into match (i.e., fi-
brotic) areas, is another important question that deserves
further study. The present study did not evaluate regional
differences in rest wall motion, and therefore the functional
consequences of the hypothesized ischemia cannot be ad-
dressed. Mitral regurgitation would be important for eval-
uating the described flows and oxidative metabolism rates
and also might be relevant for stress calculations. Although
we do not have individual quantitative data of mitral
regurgitation in these patients, mitral regurgitation worse
than grade II was not found in our patients.
Clinical implications. It has always been assumed that
myocardial ischemia does not play a role in IDC. However,
if myocardial ischemia is indeed present in patients with
IDC, it has important implications for the pathophysiology
of the disease, and it may modify drug treatment. In this
respect, it is tempting to speculate that the favorable effects
in studies with beta-blockers (Cardiac Insufficiency Biso-
prolol Study [CIBIS-1]) and also with the calcium channel
blocker amlodipine (Prospective Randomized Amlodipine
Survival Evaluation [PRAISE]) in patients with CHF and
IDC, may be partly due to their anti-ischemic effects
(33,34). In these studies more pronounced effects were
observed in patients with IDC than in those with CHF due
to coronary artery disease. A potential explanation for these
somewhat unexpected findings is the fact that patients with
CHF and IDC are basically not tested with anti-anginal
drugs, and the effects of anti-ischemic drugs may therefore
be more pronounced.
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